Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Laura Collett, DR Howard, T Munir, L McParland, JB Oughton, AC Rawstron, A Hockaday, C Dimbleby, D Phillips, K McMahon, C Hulme, D Allsup, A Bloor, P Hillmen

Research output: Contribution to journalArticle (Academic Journal)

Original languageEnglish
Publication statusPublished - 22 Aug 2017

Cite this